Company News

Share this article:

Wyeth and Catalyst Biosciences announced a worldwide collaboration for the discovery, development and commercialization of Factor Vlla products to treat hemophilia and other bleeding conditions. The deal included an upfront payment of $21 million, and total payments “could exceed $500 million,” according to the statement. Wyeth will be responsible for the manufacturing and commercialization of products resulting from the collaboration, including CB 813, an investigational candidate for the treatment of acute bleeding in patients with hemophilia.

A jury awarded J&J's Centocor Ortho Biotech $1.67 billion in a patent infringement suit against Abbott Laboratories. The patent in question was an anti-TNF class of arthritis treatments, co-owned by New York University and Centocor, according to the release. Abbott's drug Humira (adalimumab), which had sales in the billions last year, was found to infringe.

Keltman Pharmaceuticals has contracted inVentiv Selling Solutions to provide a sales team that will supplement the Flowood, MS-based wholesale pharma firm's in-house  team, maintaining in-office medicine dispensing systems for physicians.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.